Deutsche Telekom Clinical Solutions India Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 17-11-2024
- Paid Up Capital ₹ 2.15 M
as on 17-11-2024
- Company Age 11 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 35.38%
(FY 2023)
- Profit 60.97%
(FY 2023)
- Ebitda 39.64%
(FY 2023)
- Net Worth 20.62%
(FY 2023)
- Total Assets 20.16%
(FY 2023)
About Deutsche Telekom Clinical Solutions India
The Corporate was formerly known as Semana Healthcare India Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 2.15 M, as per Ministry of Corporate Affairs (MCA) records.
Pallavi Nirantar and Anjan Dutta serve as directors at the Company.
- CIN/LLPIN
U72900PN2013FTC147524
- Company No.
147524
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
23 May 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Deutsche Telekom Clinical Solutions India?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pallavi Nirantar  | Director | 23-May-2013 | Current |
| Anjan Dutta | Director | 23-May-2013 | Current |
Financial Performance of Deutsche Telekom Clinical Solutions India.
Deutsche Telekom Clinical Solutions India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 35.38% increase. The company also saw a substantial improvement in profitability, with a 60.97% increase in profit. The company's net worth Soared by an impressive increase of 20.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Deutsche Telekom Clinical Solutions India?
In 2023, Deutsche Telekom Clinical Solutions India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Deutsche Telekom Clinical Solutions India?
Deutsche Telekom Clinical Solutions India has a workforce of 249 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Deutsche Telekom Clinical Solutions India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Deutsche Telekom Clinical Solutions India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
